Review

Iwona Cicha*, Christoph D. Garlichs and Christoph Alexiou

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Abstract: Recent years brought about a widespread interest in the potential applications of nanotechnology for the diagnostics and the therapy of human diseases. With its promise of disease-targeted, patient-tailored treatment and reduced side effects, nanomedicine brings hope for millions of patients suffering of non-communicable diseases such as cancer or cardiovascular disorders. However, the emergence of the complex, multicomponent products based on new technologies poses multiple challenges to successful approval in clinical practice. Regulatory and development considerations, including properties of the components, reproducible manufacturing and appropriate characterization methods, as well as nanodrugs' safety and efficacy are critical for rapid marketing of the new products. This review discusses the recent advances in cardiovascular applications of nanotechnologies and highlights the challenges that must be overcome in order to fill the gap existing between the promising bench trials and the successful bedside applications.

Keywords: cardiovascular diseases; cardiovascular drug-delivery nanosystems; clinical trials; diagnostic nanoparticles; nanomedicine.

*Corresponding author: Iwona Cicha, PhD, Cardiovascular Nanomedicine Unit, Section of Experimental Oncology and Nanomedicine, University of Erlangen-Nuremberg, Glückstr. 10a, 91054 Erlangen, Germany, Phone: +49 9131 8543953, Fax: +49 9131 8534282, E-mail: Iwona_Cicha@yahoo.com
Christoph D. Garlichs and Christoph Alexiou: Section of Experimental Oncology and Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship, ENT Department, University Hospital Erlangen, Erlangen, Germany

Introduction

Cardiovascular diseases (CVD) account for almost 50% of all deaths in Europe and around 30% of all deaths worldwide (1). According to the Global Burden of Disease Study 2010, when combining years of life lost and years lived with disability, coronary heart disease and stroke rank first and third, respectively (2). Although the clinical management of CVD has improved in Western Europe leading to about 20% decrease in age-standardized death rates for CVD in the last two decades (1), the number of CV deaths is predicted to increase from 17.1 million worldwide in 2004 to 23.6 million in 2030 due to the increasing impact of obesity and metabolic syndrome. In this paper, we review the potential applications of nanotechnologies in cardiovascular medicine, the current stand of clinical studies and pilot trials, and the obstacles to overcome before the nanomedical approaches can be safely introduced to the clinical practice.

Potential applications of nanotechnologies in cardiovascular medicine

Nanomedicine offers a unique platform for novel approaches to the diagnosis and therapy of cardiovascular diseases. The possible applications range from plaque imaging and thrombus detection to the targeted drug-delivery, stent endothelialization and blood vessel regeneration. This subchapter summarizes recent advances in the preclinical experimental efforts to implement nanomedical approaches to cardiovascular disorders.

Nanosystems for detection and characterization of cardiovascular disorders

Imaging modalities and nanoprobes

The molecular imaging techniques routinely used in cardiovascular medicine are constantly being optimized to better detect atherosclerotic plaques, but none of the modalities is without limitations (3). Whereas magnetic resonance imaging (MRI), a noninvasive and nonionizing imaging technique has an excellent resolution but
low sensitivity, positron emission tomography (PET) has the highest sensitivity of all imaging modalities and an unlimited penetration depth. These advantages are counterbalanced by its low resolution, very high cost, and radioactivity. Optical fluorescence imaging, suitable for e.g., imaging plaque endothelium, can be difficult to quantify in tissues more than a few millimeters in depth. Thus far, the preclinical studies performed in order to investigate the diagnostic and therapeutic benefit of nanoparticles in atherosclerosis mostly utilized the MRI contrast agents, which consist of suspended colloids of nanoparticles and, when injected during imaging, reduce the T₂ signals of absorbing tissues. In particular, either paramagnetic gadolinium chelates or iron oxide-based contrast agents, such as superparamagnetic iron oxide (SPIO, particle size of 120–180 nm) and ultrasmall superparamagnetic iron oxide (USPIO, 60 nm particle size) have been used. Recently, multi-modal contrast agents or imaging probes detectable with multiple molecular imaging techniques have emerged, which promise a better sensitivity and accuracy of atherosclerotic plaque detection and classification (4, 5).

Detection of atherosclerotic lesions

Early identification and aggressive pharmaceutical and/or interventional treatment of atherosclerotic plaques can help to reduce the incidence of acute ischemic events. Conjugating nanoparticles to specific ligands that target endothelial cell adhesion molecules [vascular cell adhesion molecule-1 (VCAM)-1 (6, 7), as well as E- and P-selectins (8, 9)] has proven a successful experimental approach to noninvasive in vivo imaging of the early stages of atherosclerosis. Imaging nanoparticles have also been implemented for vulnerable plaque identification based on their ability to detect intraplaque macrophages, lipids, angiogenesis, apoptosis, or thrombotic deposits [reviewed in detail in (10)]. Below, several approaches to atherosclerotic plaque characterization are briefly outlined. Macrophage burden in atherosclerotic plaques in vivo can be estimated using unlabeled superparamagnetic iron oxide nanoparticle (SPION), as shown in hyperlipidemic rabbits by differential phase optical coherence tomography (OCT) (11) and MRI (12, 13) as well as in atherosclerotic plaques of ApoE-deficient mice (14). However, as the uptake of SPION is not specific to the plaque macrophages (15), targeting of macrophages [e.g., with homing peptide LyP-1 (16, 17)] and macrophage receptors [e.g., CD36-targeting gadolinium-containing liposomes (18, 19) and scavenger receptor-A-targeting iron oxide nanoparticles (20)] is helpful to enhance the labeling efficiency of the particles in vivo. Lipoproteins, natural nanoparticles of 5–20 nm diameter, represent good candidates for the transfer of imaging nanoparticles into the lesions. High-density lipoproteins (HDL)-like nanoparticles enriched with gadolinium have been reported to specifically image plaques in vivo (21, 22). Detection of vulnerable plaques in mice was also facilitated by anti-mouse OxLDL polyclonal antibodies conjugated to USPIO (23).

Imaging apoptotic cells is another possible approach to identifying plaques with vulnerable morphology, as shown by studies utilizing phosphatidylserine-targeting peptides linked to USPIO (24), as well as annexin A5-labeled SPION (25) and gadolinium nanoparticles (26). Neangiogenesis, a common feature of advanced vulnerable plaques can also constitute an MRI detection target for plaque characterization, as shown in atherosclerotic rabbits (27) administered gadolinium-containing perfluorocarbon nanoparticles targeted to αβ₃-integrin, one of the key mediators of neovessel formation (28, 29).

Thrombus formation that occurs on the luminal surface of atherosclerotic plaques presents yet another target for detection by MRI. For this purpose, anti-fibrin antibodies conjugated to gadolinium-diethylene trimine pentaacetic acid (DTPA)-perfluorocarbon nanoparticles were successfully used (30), as well as the fibrin-targeting CREKA peptide-bound lipopeptide nanoparticles (31), or a commercially available gadolinium-linked fibrin-binding peptide EP-2104R (32). These studies indicate that employing targeted nanoparticles to refine the available non-invasive techniques should not only advance the detection of vulnerable plaques but also enable monitoring the disease progression and therefore improve the risk stratification.

Detection of high-risk aneurysms

Abdominal aortic aneurysms (AAA) occur in 5% to 9% of the population over the age of 65 years and are the tenth leading cause of death in Western countries (33). Several recent reports show the feasibility of nanotechnological approach to in vivo aneurysm detection and characterization using MRI and near-infrared fluorescence imaging (NIRF). As an example, SPION-enhanced MRI was applied to detect early AAA in ApoE-deficient mice (34). SPION uptake and abdominal aortic diameter were found to correspond to the numbers...
of iron-laden macrophages in the aneurysm. Another approach was tested by Klink et al. (35), who showed that intravenous administration of gadolinium-based fluorescent micellar nanoparticles functionalized with a collagen-binding protein resulted in a significantly higher magnetic resonance signal enhancement in the aneurysmal wall compared with nonspecific micelles. High-resolution MRI allowed longitudinal monitoring of the AAA progression and the increase of the aortic diameter, enabling the discrimination between stable and rupture-prone aneurysms. Nearly in parallel, a study by Kitagawa et al. evaluated NIRF imaging of AAA using Arg-Gly-Asp (RGD)-conjugated human ferritin nanoparticles labeled with Cy5.5. In a mouse model of AAA, a significantly higher signal in AAA relative to non-diseased regions was obtained using RGD-ferritin nanoparticles than with unconjugated nanoparticles (36). These studies suggest that targeting nanoparticles allow more comprehensive characterization and prognosis of aneurysmal disease.

### Imaging inflammation after cerebral or cardiac ischemia

Vascular damage and inflammation critically affect patients’ outcomes after stroke. Nanoparticle-based contrast agents can be applied to characterize the extent of inflammation, as demonstrated by several studies in an experimental murine model of cerebral ischemia. In those early studies (2001–2004) by Rausch et al. (37, 38), Kleinschnitz et al. (39), and Schroeter et al. (40), SPION have been utilized for MR imaging of the brain inflammation after stroke and showed macrophage-specific accumulation in the infarcted brain region. The ability of USPIO-enhanced MRI to detect inflammatory response surrounding the ischemic regions has subsequently been confirmed by Wiart et al. (41). Most recently, Frechou et al. (42) applied USPIO conjugated to VCAM-1-targeting peptide in order to detect cerebral expression of VCAM-1 after experimental stroke in mice. The study showed that such targeted MRI contrast agent can be useful for characterizing the vascular damage associated with cerebral ischemia.

Following myocardial infarction (MI), uncontrolled inflammation and adverse cardiac remodeling can ultimately result in heart failure. Thus far, very small iron oxide nanoparticles (43) and micrometer-sized iron oxide particles (44) have been tested to assess inflammation in murine models of MI showing their ability to characterize the course of pathologic process after myocardial ischemia.

### Nanosystems for diagnosis of cardiovascular disorders

Nanotechnology-based signal amplification for biosensing has been a rapidly developing field. Several categories of nanomaterials such as gold nanoparticles, magnetic oxide nanoparticles, or quantum dots have multiple potential applications in this important aspect of cardiovascular diagnostics. This subchapter focuses on the application of nanosystems for the estimation of disease biomarkers.

#### Estimating the burden of thrombosis

Intravascular thrombosis, the formation of life-threatening obstructive blood clots within the vessels, underlies a number of cardiovascular disorders such as heart attack, ischemic stroke, pulmonary embolism, and deep vein thrombosis (45, 46). Within the coagulation cascade, thrombin is the most important serine protease (47), but the diagnostic tests are lacking that directly reflect its activity in clinical settings. Recently, Lin et al. described the development of novel urinary nanomarker assay based on thrombin-sensitive iron oxide nanoparticles that allows detection of thrombin activity in vivo (48). The nanomarkers were produced by coupling iron oxide nanoworms with thrombin-cleavable peptides linked to a synthetic reporter system, composed of protease-resistant peptide, glutamate-fibrinopeptide B, which was modified at the termini with ligands detectable by an immunoassay (fluorescein, or Alexa488, and biotin). In a mouse model of pulmonary embolism induced by thromboplastin (49), the authors showed that the circulating nanomarkers could access the local sites of thrombosis and release the reporters, the urinary clearance of which was detectable by ELISA with high sensitivity and significantly correlated with the disease burden as estimated by the histochemically analyzed amount of fibrin deposited in the lungs (48).

The imaging approach to thrombosis detection using microCT has been recently tested in a mouse model of carotid thrombosis using glycol chitosan (GC)-gold nanoparticles. The study showed that these nanoparticles allowed both the detection of primary and recurrent thrombi, and the monitoring the therapeutic efficacy of thrombolysis with tissue plasminogen activator (tPA). Due to a long circulating half-life, GC-gold nanoparticles remained available for entrapment into fibrin matrix for up to 3 weeks, allowing repetition or ongoing monitoring of thrombogenesis and thrombolysis (50). Given the need of rapid and reliable in vivo assessment of the thrombotic
risk in patients with cardiovascular diseases in order to improve the diagnosis, risk stratification, and management of thrombotic syndromes, those systems represent a very attractive platform for use in clinical practice.

**Diagnosis of acute coronary syndromes**

Molecular biomarkers are used as objective indicators of myocardial injury. About 30% of patients with non-ST-elevation acute coronary syndrome present without evidence of myocardial necrosis using available assays for cardiac troponin, the biomarker of choice for the serologic diagnosis of acute coronary syndromes. More sensitive assays for troponin are urgently needed to enable an earlier detection of MI and identify patients who are at risk of short-term major adverse cardiac events. Nanotechnology offers several solutions to the drawbacks of the existing cardiac biomarker assays. One of them was recently reported by Cowles and Zhu (51), who applied the dual signal amplification method for the measurement of cardiac troponin I (cTnI) in human serum. The technique consists of sandwich-ELISA, in which detection antibodies are linked by biotin-avidin complex to semiconductor nanoparticle labels (quantum dots) of zinc sulfide. By lowering pH, the release of zinc ions is induced (first step of signal amplification), which act as co-factors for carbonic anhydrase and, at normalized pH, lead to a concentration-dependent activation of this enzyme. Upon addition of substrate, fluorescein diacetate, enzyme activity produces fluorescent product (second step of signal amplification) the concentration of which is measured spectrophotometrically. Using this technique, cTn1 assay was developed and tested on human serum samples, showing superior detection resolution and simple handling (51).

In a study by Ling et al. (52), magnetic resonance relaxometry was used to noninvasively monitor changes in the relaxation properties of antibody-coated magnetic particles when they aggregate upon exposure to a biomarker of interest. As the single-point measurements often do not reflect the directions of the underlying pathologic process, thus hindering diagnostic and prognostic decisions, the authors of this innovative method applied implantable devices containing sensors of three clinically relevant cardiac biomarkers: cTnI, creatinine kinase and myoglobin, to continuously monitor biomarker levels for up to 72 h, with a detection level as low as the pg/mL range. In a mouse model of MI, the detected biomarker levels and changes over time differed between experimental and control groups and correlated with infarct size.

These studies underscore the enormous potential of nanotechnologies for improved biomarker detection and thus patients’ diagnosis.

**Nanosystems for monitoring the treatment efficacy**

Nanoparticle-based imaging may serve not only as a biomarker to identify vulnerable lesions, angiogenesis, or ischemic regions, but can also provide a tool to monitor the therapeutic effectiveness of medication. In a study by Morishige et al. (13), SPION-enhanced MRI was used to monitor the effects of rosuvastatin on macrophage burden in atherosclerotic plaques of ApoE-deficient mice (14). Serial USPIO-enhanced MRI scans were furthermore utilized to monitor the therapeutic effects of an anti-inflammatory drug minocycline in a mouse model of stroke (53). The authors concluded that although there are still several limitations to overcome before the application of this technique in clinical practice, USPIO-enhanced MRI might provide useful surrogate markers for detecting a therapeutic effect in pre-clinical studies.

Another approach to the long-term monitoring of vascular system is represented by encapsulation of SPION into red blood cells in order to ensure their increased blood circulation time. As shown in a paper by Rahmer et al. (54), SPION-loaded RBCs can be imaged in the blood pool of mice several hours after injection, and their presence in circulation for up to 24 h was confirmed by spectroscopic quantification of the iron concentration in mouse blood samples collected after injection of SPION-loaded RBCs. Using this novel approach, long-term monitoring in cardiovascular diseases (e.g., monitoring the bleeding after stroke, imaging vessel architecture during interventional procedures, or controlling the treatment efficacy) can be envisioned without the necessity of the repeated administration of contrast agents.

**Nanosystems for vascular treatment and regeneration**

Although pharmacologic agents for the treatment of cardiovascular disorders are available, the conventional therapy using systemic delivery methods has several serious drawbacks, such as considerable side-effects or...
low efficacy at tolerated doses. To overcome the problems associated with traditional therapeutic approaches, the targeted nanoparticles can be used as transport vehicles that allow local targeted drug delivery to disease-specific cells or tissues and thus concentrate the therapeutic agent at the site of action. In this manner, drug cytotoxicity is expected to be reduced by (a) targeted tissue accumulation and (b) reduction of the required dosis. Additionally, as the nanocarrier systems are larger than 5 nm in diameter (ca. 10–200 nm) they evade renal clearance thus increasing circulation half-life of the transported drugs.

**Nano-sized drug carriers**

Among the materials most commonly used for cardiovascular drug-delivery systems are the nanoparticles or nanoshells made of natural or synthetic polymers, such as liposomes and lipidotls, dextrans, poly(lactic-co-glycolic acid) (PLGA), polyacrylates, as well as metal or metal oxide nanoparticles (e.g., gold, silver, SPION), and quantum dots. Several of the commonly tested drug-carrier systems [reviewed in detail in (55)] are briefly outlined below.

**Liposomes** are composed of a lipid bilayer consisting of amphipathic phospholipids (primarily phosphatidylcholine) that enclose an interior aqueous space (56). The head groups of phospholipids are usually functionalized with maleimide, which allows conjugation to antibodies or other ligands, and/or with polymerizable moieties to improve stability [e.g., polyethylene glycol (PEG)-ylated stealth liposomes]. Among the drug-delivery systems, liposomes have relatively low toxicity and a good therapeutic index (56, 57). A subgroup of those compounds, cationic liposomes, originally used as transfection reagents for gene or siRNA delivery, can be easily functionalized with antibodies or ligands. Among their advantages as a drug-delivery platform are the ease of preparation, commercial availability and overall low immunogenicity (58), which is expected to enable safe and repeated administration.

**PLGA, poly(lactic-co-glycolic acid)**, is the most common biodegradable polymer Federal Drug Agency (FDA)-approved for use in humans. As PLGA degradation products (lactic acid and glycolic acid) are easily metabolized and easily eliminated from the body, the systemic toxicity associated with PLGA application is low (59).

**Dextrans** are stable glucose polymers that contain functional groups for derivatization (60). Apart from stability, several other advantages such as water solubility, and drug protection from degradation which allows sustained release of active compounds, make them a suitable platform for delivering pharmaceutical agents (61).

**Gold nanoparticles** consisting of a dielectric core of silica coated with a metallic layer of gold, are available in various sizes and forms (62) and can be used for e.g., as biosensors, or photoactive agents for optical imaging, for photothermal ablation therapy, or as drug carriers. SPIONs consist of iron oxide core, often coated with organic materials such as fatty acids, polysaccharides, or polymers (63, 64). The magnetic properties of SPIONs allow the remote control of their accumulation by means of external magnetic field, as well as their application for hyperthermia-therapy. Conjugation SPIONs with drugs, in combination with an external magnetic field to target the nanoparticles (so called “magnetic drug targeting”, Figure 1), has additionally emerged as a promising strategy of drug delivery, which results in increased drug payloads in the target tissue, at the same time reducing their systemic dose and toxicity as demonstrated by the in vivo studies from our group (65–67).

**Cell-based therapies**

Due to the safety concerns associated with the use of cell-labeling strategies, development of low side-effect agents for tracking of the stem cells has been challenging (69). Because of this, it is difficult to evidence the fate of those cells in the human studies, despite the promising results with regard to their regenerative capacities in cardiovascular diseases. In one of the pioneering works, Himes et al. (70) used embryonic stem cells loaded with SPION for long-term monitoring of their fate following intramyocardial injection in a mouse model of MI. The subsequent studies by Sadek et al. (71) utilized the USPIO-based contrast agent ferumoxide (Endorem/Feridex IV) in combination with transfection agent protamine sulfate for labeling and tracking of bone marrow-derived human mononuclear cells and C2C12 skeletal myoblasts within rat myocardium. In the settings of MI, SPION-labeling of mesenchymal stem cells (MSCs) was furthermore utilized for cell tracking and the simultaneous evaluation of their long-term therapeutic potential i.e., left ventricular ejection fraction assessment (72). SPION-enhanced MRI has moreover been tested for tracking endothelial progenitor cells in a rat model of MI (73).

To demonstrate the potential of nano-labels for stem cell tracking during ischemic brain injury, ferumoxide-protamine sulfate label has been used for MSC labeling in the experimental cerebral infarction (74). Ferumoxide has also been tested as an MRI label for human neural stem cells (75). Other studies utilized microgel iron oxide nanoparticles (76), and SPION-loaded cationic
nanovesicles (77) in different models of murine stroke for labeling human and rat MSCs, respectively. Wang et al. (78) developed a novel fluorescent-magnetite-nanocluster with high MRI sensitivity and high labeling efficiency for MSCs, which allowed tracking their migration and accumulation in the ischemic region in a mouse stroke model. Similar results were obtained using fluorescent mesoporous silica-coated SPION for labeling neural progenitor cell (79). Both intravenous administration and implantation of such labeled cells in the mouse brain hemisphere contralateral to the ischemic injury region allowed tracking their migration to the lesion site using MRI. Taken together, these studies indicate that SPIONs represent a highly effective platform for labeling and MRI tracking of therapeutic stem cells in the context of CVD.

In a most recent study by Riegler et al. (80), MSC loading with SPION was used in order to magnetically target the cells to the sites of vascular injury induced by balloon angioplasty in rabbits. This study demonstrated the feasibility of magnetic cell delivery approach for localized accumulation of therapeutic cells in the injured arterial regions.

**Stroke treatment**

After cerebral ischemia and reperfusion, the oxidative stress and inflammation may contribute to the
post-ischemic brain injury, affecting patients’ outcomes. Nanoparticles can be used for targeted delivery of large payloads of antioxidant enzymes or reactive oxygen species scavengers into the affected tissue. This approach has been tested in mouse ischemic brain using platinum nanoparticles (Pt-NPs), which themselves are potent scavengers of superoxide anion (81, 82). Compared with vehicle, treatment with Pt-NPs significantly improved the motor function and greatly reduced the superoxide production and the infarct volume, indicating that the antioxidant properties of Pt-NPs can contribute to neuro-protection following the ischemic stroke (81, 82).

In their recent paper, Yun et al. (83) generated various nanoparticles (liposomes, polybutylcyanoacrylate (PBCA), or PLGA) that contained active superoxide dismutase (SOD), and were tagged with antibodies directed against the N-methyl-D-aspartate (NMDA) receptor 1. In a mouse model of cerebral ischemia, the nanoparticles containing SOD showed protection against ischemia and reperfusion injury when applied after stroke with a 50%–60% reduction in infarct volume, reduced inflammatory markers, and improved behavior in vivo.

Another treatment approach utilizing PEGylated-lipid nanoparticles that go across the blood-brain barrier was reported by Lu et al. (84). The nanoparticles encapsulating 3-n-butylphthalide were conjugated to Fas ligand antibody that selectively present on brain ischemic region. Those nanoparticles effectively accumulated in ischemic region of mouse brain, and resulted in significant improvements in brain injury and in neurological deficit after ischemia, with the significantly reduced dosages vs. free 3-n-butylphthalide. These studies show that targeted nanoparticles containing protective factors may be viable candidates for the treatment of stroke-induced ischemic brain injury.

Thrombolysis

Rapid recanalization of an occluded artery is essential for better outcomes in acute myocardial infarction or stroke. The current fibrinolytic therapy can be rapidly administered, but does not achieve a high reperfusion rate and is associated with considerable side-effects (85). Additionally, many patients are ineligible for systemic thrombolytic therapy, e.g., due to delayed admission to the hospital after symptom onset, or because of recent surgery, bleeding, etc. Development of delivery systems for rapid thrombolysis, characterized by a strong fibrinolytic effect and low bleeding risk, is therefore one of the most urgent tasks in cardiovascular medicine.

Thrombolysis represents the most important target of direct anticoagulants within the coagulation cascade. Two recent publications from the group of Wickline (86, 87) investigated the effects of the nanoparticle-bound potent thrombin inhibitor, d-phenylalanyl-l-prolyl-l-arginylchloromethyl ketone (PPACK) in a mouse model of acute arterial thrombosis due to the photochemical injury of the carotid artery. PPACK-perfluorocarbon nanoparticles outperformed both heparin and uncomplexed PPACK in inhibiting thrombosis, and formed a local clotting barrier that continued to manifest clot inhibition even as systemic effects rapidly diminished (86). Administration of PPACK-liposomes prior to the injury significantly delayed the time to arterial occlusion as compared to free PPACK. Systemic anticoagulant profiles revealed a rapid return to control levels within 50 min, whereas the antithrombin activity was maintained at the injury site (87). The establishment of a potent and long-acting anticoagulant surface over a newly forming clot with the use of thrombin targeted nanoparticles that do not require systemic anticoagulation to be effective offers an alternative site-targeted approach to the management of acute thrombosis.

Current thrombolytic therapy by infusion of tPA is characterized by several drawbacks, including low efficacy combined with a high risk of bleeding complications (85). Therefore, several innovative strategies aiming at targeted and/or local applications of plasminogen activators have been designed. The possibility of magnetic-targeting of tPA for local thrombolysis was investigated by Ma et al. in a rat embolic model (88). Polyacrylic acid-coated magnetite nanoparticles bound to tPA (tPA equivalent of 0.2 mg/kg) were administered intraarterially under guidance with the external magnet moving back and forth along the iliac artery. tPA-NPs restored the iliac blood flow within 75 min to 82% of that before the clot lodging, whereas equivalent amount of free tPA exerted no improvement on hemodynamics. The authors concluded that magnetic tPA-NPs allow reproducible and effective target thrombolysis with <20% of the regular dose of free tPA.

Recently, a novel drug delivery nanosystem was described comprising tPA, basic gelatin and zinc acetate (89). Within this nanosystem, tPA activity was reduced in vitro to approximately 50% of free tPA and was fully recoverable by the application of low frequency ultrasound. In a swine acute myocardial infarction model, plasma tPA activity after intravenous injection of nanoparticles was approximately 25% of free tPA and was recovered completely by transthoracic ultrasound application, with significantly higher tPA activity near the affected coronary artery than in the femoral artery region. In comparison to treatment with free tPA (0.447 mg/kg),
which recanalized the occluded coronary artery in only 1 of 10 swine, nanoparticles containing the same dose of tPA with ultrasound activation achieved recanalization in 9 of 10 swine within 30 min, suggesting that this nanosystem bears promising potential for improved thrombolysis.

Another novel and extremely promising nanomedical strategy of targeted tPA delivery to stenotic arteries employing hemodynamic forces was recently described by Korin et al. (90). Since occlusions in blood vessels result in local increases in shear stress leading to platelet activation and clotting, the authors designed micro-aggregates of PLGA nanoparticles coated with tPA. These micro-aggregates are not affected by physiologic flow conditions with shear stress values up to 70 dyn/cm², but exposed to abnormally high shear stress in the regions of vascular occlusion/stenosis, undergo break up followed by local drug release. As compared with free drug, the shear-activated tPA-coated nanoparticles induced rapid dissolution of arterial thrombi induced by the exposure of mouse mesenteric arteries to ferric chloride, with complete clearance of occluding thrombi within 5 min after application (90). Moreover, upon infusion of lethally large fibrin clots, the immediate application of the shear-activated tPA-coated nanoparticles increased survival by 80%. The doses of shear-activated tPA-nanoparticles required for clot dissolution were about 100-times lower than the doses required for achieving comparable effects with free drug (90). This strategy, utilizing a universal hemodynamic phenomenon of shear stress increase upon reduction in vessel diameter should result in a broad applicability for all occlusive vascular conditions, including e.g., treatment of stenotic atherosclerotic plaques, pulmonary emboli, and ischemic stroke.

Myocardial infarction

Regeneration of the infarcted heart is one of the most important therapeutic goals in cardiovascular medicine. In search for a suitable nanotechnological platform for regenerative and anti-remodeling drug delivery, Paulis et al. (91) investigated the penetration of different paramagnetic lipid nanoconstructs (micelles, 15 nm in size, or liposomes, ca. 100 nm in size) in the infarct region. The authors showed that both in acute and chronic myocardial infarction settings, micelles permeate the entire infarct area, and can thus represent a good system for the delivery of cardioprotective drugs and for non-invasive monitoring of the infarct size by MRI (91). Several recent publications have furthermore tested whether nanoparticulate drug- or gene-delivery is capable of stimulating the regeneration of ischemically damaged hearts. Binsalamah et al. (92) utilized chitosan-alginate nanoparticles loaded with proangiogenic and cardioprotective placental growth factor (PIGF). The intramyocardial injection of these constructs provided a sustained slow-release PIGF therapy, resulting in decreased scar formation, improved left ventricular function and an anti-inflammatory systemic cytokine profile. Similar approach was tested by Chang et al. (93), who utilized PLGA nanoparticles conjugated with insulin-like growth factor-1 (IGF-1). Single post-MI intramyocardial injection of these nanoparticles resulted in prolonged retention of IGF-1 in the myocardium, which was sufficient to prevent cardiomyocyte apoptosis, and to reduce infarct size and improve left ventricular function at 21 days after MI.

Gene therapy represents yet another possibility to improve patients’ outcomes following MI. Zhang et al. (94) applied externally controlled magnetic nanobeads conjugated to adenoviral vectors-encoded human vascular endothelial growth factor (VEGF) gene. Following intravenous administration, the nanobeads were accumulated in the myocardial region by external epicardial magnet, resulting in a good transduction efficiency and a strong VEGF gene expression in the ischemic zone of the heart. This led to improved left ventricular function, increased capillary and arteriolar density and reduced the collagen deposition in infarcted region, indicating that magnetic targeting enhances local transduction efficiency, and supports cardiac repair. Gene silencing was also tested in a recent study by Liu et al. (95) as a promising tool for regulating gene expression following MI. Oligo-arginine-conjugated dendrimer loaded with siRNA against angiotensin 2 type 1 receptor (AT1R) prevented the receptor upregulation in vivo and improved the recovery of cardiac function after the ischemia-reperfusion myocardial injury. These studies demonstrate the enormous potential of nanoparticle-based technology for improved clinical therapy of MI and ischemic CVD.

Plaque stabilization

Atherosclerotic plaque stabilization is the aim of the current pharmacologic strategies, including statin therapy. As the experimental approaches to nanoparticle-based treatment of different stages of atherosclerosis are reviewed in detail elsewhere (10), this paragraph will only briefly list some of the potential targets for lesion stabilization. As an example, interventions with an inhibitory effect on macrophages have thus far been tested in ApoE-deficient mice utilizing pitavastatin-loaded PLGA nanoparticles (96). As compared with pitavastatin alone,
the nanoparticle-mediated delivery of pitavastatin to circulating inflammatory monocytes prevented plaque destabilization and rupture by inhibiting their inflammatory activity and recruitment to the lesions. In a study by McCarthy et al., the administration of magnetofluorescent nanoparticles with light-activated therapeutic moieties which allow phototoxic activation (97), allowed an efficient focal ablation of inflammatory macrophages upon irradiation of the plaques. Such nanoparticles inducing focal toxicity confined to macrophages, without affecting endothelial or smooth muscle cells (SMCs), could have a durable plaque-stabilizing effect.

Another vital target for plaque-stabilizing therapies is represented by plaque neovascularization, as shown by the studies of Winter et al. (98) who applied \( \alpha\beta_3 \) integrin-targeting SPION for site-specific delivery of antiangiogenic drug fumagillin in a rabbit model of atherosclerosis. These studies demonstrated superior antiangiogenic activity and reduced toxicity of \( \alpha\beta_3 \) targeting, fumagillin-carrying nanoparticles, as compared with systemic drug application (98). Targeted nanoparticles for local drug delivery can thus improve the therapeutic effect of current pharmacologic compounds for plaque stabilization.

### Application of nanoparticles to prevent in-stent restenosis

Stent implantation allows recanalization of stenosed vessels, but is often related with complications, such as stent thrombosis and restenosis. Stent thrombosis is induced by the disruption of the endothelial monolayer and necessitates lengthy dual-antiplatelet therapy (DAPT). Stent implantation additionally results in an excessive SMC proliferation, which in the longer term can cause restenosis and vessel occlusion (99, 100). To prevent this process, drug-eluting stent (DES) containing anti-proliferative drugs are used. In clinical trials, DES has been shown to significantly reduce restenosis as compared to bare metal stents (101, 102). However, drug-induced inhibition of SMC proliferation also inhibits the re-establishment of a healthy endothelium, thus increasing the risk of stent-related thrombosis (103–105). Therefore, new stent systems targeting SMCs without adverse effects on endothelial cells are urgently needed. Several nanotechnological approaches to this issue have been reported, some of which are discussed below.

Polymers liposome nanoparticles targeted to chondroitin sulfate proteoglycans that encapsulated prednisolone were tested in a study by Joner et al. in order to prevent neointimal hyperplasia following bare metal stent implantation in rabbit (106). These nano-constructs specifically targeted the sites of stent-induced injury (106), increased the tissue concentration of prednisolone in stented arteries by 100-fold as compared to contralateral nonstented arteries, and resulted in significant suppression of in-stent neointimal growth (106). This indicates that site-specific targeting of anti-inflammatory drug-loaded nanoparticles to the stented arteries can constitute a suitable method for the prevention of in-stent restenosis.

Another approach was tested by Tsukie et al. (107), who utilized a novel bioabsorbable polymeric nanoparticle-eluting stent (NES) that provides more sustained delivery of therapeutic agents than the common dip-coated DES (108). For this purpose, nanoparticles were produced containing pitavastatin. In a pig coronary artery stent model, the effectivity of in-stent stenosis inhibition by statin-NES equaled that of polymer-coated sirolimus-eluting stents, but was not accompanied by delayed endothelialization as observed in the sirolimus group. These findings indicate that inhibition of in-stent stenosis without delaying endothelial healing is possible (107).

A promising strategy to increase the rate of stent endothelialization was reported by Polyak et al. (109). In this study, endothelial cells expressing luciferase were preloaded with biodegradable polymeric superparamagnetic nanoparticles in order to enable their magnetic targeting to the steel surfaces of intraarterial stents. In the presence of a uniform external magnetic field, magnetic nanoparticle-loaded bovine aortic endothelial cells were successfully targeted to stents implanted in rat carotid arteries. Optical imaging confirmed significantly greater luciferase expression at the stented arteries treated with magnetically-labeled endothelial cells compared with nonmagnetic controls. Nanotechnology thus offers multiple strategies for improving the safety profiles of stents following cardiovascular interventions.

### Tissue engineering and vessel endothelialization

Functionalized tissue-engineered vascular grafts do not only possess potential for applications in peripheral and coronary bypass surgery but are also attractive to the pediatric surgery for congenital heart defects. Cell loading with magnetic nanoparticles is one of nanotechnological strategies that have been often applied to vascular tissue fabrication. This technique allows the deposition of loaded fibroblasts, SMCs and endothelial cells on the luminal side of the tubular scaffolds by means of external magnetic force as described by Ito, Perea and Gonzalez-Molina (110–113). Moreover, the magnetic tissue fabrication (114), was recently tested in vitro for cardiac tissue
engineering. Using cardiomyocytes labeled with magnetic nanoparticles, the formation of a ring-shaped tissue that possessed a multilayered cell structure and contractile properties was achieved. These results indicate that magnetic tissue fabrication is a promising approach both for vessel and for cardiac tissue engineering.

**Clinical applications: state of the art**

Comparing with the vast number of bench research reports focusing on cardiovascular applications of nanotechnologies that have been published in the recent years, the reported clinical trials are scarce (Table 1). Below, several early cardiovascular imaging studies using magnetic nanoparticles and the few recent pilot trials involving nanosystems are highlighted.

**Pilot studies – cardiovascular imaging**

The majority of the clinical trials involving nanoparticles dates back to the beginning of the previous decade (2001–2004). These studies, most of which originated from the group of J.H. Gillard, utilized USPIO-based contrast agents in order to detect and characterize atherosclerotic plaques, based on the specific incorporation of USPIO by activated macrophages [reviewed in (136)].

Early clinical studies using ferumoxtran (Sinerem/Combidx) have shown that USPIO accumulate in atherosclerotic plaques in aorta and pelvic arteries (115), as well as carotid plaques (116, 117), resulting in areas of focal signal loss on in vivo MR images that correspond to accumulation of iron particles in ex vivo specimens. A study by Kooi et al. (117) performed on 11 symptomatic patients scheduled for carotid endarterectomy demonstrated that USPIO accumulated predominantly in macrophages in ruptured and rupture-prone atherosclerotic lesions, whereas hardly any USPIO were taken up in stable plaques (117).

A clinical study from the group of J.H. Gillard confirmed the ability of USPIO-enhanced MRI to identify plaque inflammation by accumulation of USPIO within macrophages in stenotic carotid plaques (118). In that study, areas of signal intensity reduction, corresponding to USPIO- and macrophage-positive histological sections, were visualized in 7 of 8 patients receiving ferumoxtran. These data were subsequently validated on 30 symptomatic patients, showing USPIO enhancement in 90% patients with severe stenosis (119). A more recent study used USPIO to compare 10 patients with symptomatic and 10 with asymptomatic carotid stenosis (137). In symptomatic patients, significantly more focal areas of signal drop were observed than in asymptomatic group, indicating increased inflammatory infiltrates. Interestingly, focal areas of signal reduction were also detected in some asymptomatic plaques suggesting that USPIO-enhanced MRI is capable of identifying inflammation within otherwise morphologically “stable” plaques. Subsequent USPIO studies, performed in 40 patients with carotid stenosis (120), confirmed that the patients with asymptomatic carotid atheroma contralateral to the symptomatic disease showed more inflammatory activity than the completely asymptomatic cohort, despite a mean lower grade of luminal stenosis (46% vs. 63%). These findings were corroborated by a further study that compared the degree of inflammation on USPIO-enhanced imaging between asymptomatic carotid plaques in patients with coronary artery disease (CAD) and in individuals with a carotid stenosis who were completely asymptomatic in all vascular regions (121). Patients with CAD had more inflammatory activity within their carotid atheroma than did the completely asymptomatic cohort despite a mean lower degree of luminal stenosis (59% vs. 65%). The authors concluded that inflammatory activity may be a significant risk factor in asymptomatic disease and USPIO-enhanced MRI may prove a useful technique to improve the risk stratification of patients with carotid stenosis. In 2013, a new study from the group of J.H. Gillard was published, investigating for the first time the feasibility of longitudinal sequential MR imaging before and 36 h after USPIO infusion at 0, 6, and 12 months, in 10 patients with a moderate asymptomatic carotid stenosis (122). The patients, none of whom received pharmacotherapy, remained asymptomatic within the course of the study and there was no statistical difference in their USPIO uptake between the three time points. Comparing the quadrant signal before USPIO infusion, a good agreement over the 1-year period was observed. The quadrant signal detected after USPIO infusion was in a good agreement between 0 and 6 months, and in moderate agreement between 0 and 12 months, suggesting that inflammation within the carotid plaque is a changeable and dynamic process. Apart from important information on quantitative reproducibility of the technique, this study provided evidence that within the 6 months, USPIO nanoparticles were cleared out of the atherosclerotic plaque. Importantly, no adverse effects following multiple USPIO infusions were observed (122), indicating that this technique is clinically safe and applicable, also for the future longitudinal studies involving pharmacologic interventions.
Table 1  Potential nanomedical approaches to cardiovascular diagnosis and treatment. Example pre-clinical and reported clinical studies are listed.

<table>
<thead>
<tr>
<th>Example pre-clinical studies</th>
<th>Application</th>
<th>Clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular imaging</strong></td>
<td>Atherosclerotic plaque</td>
<td>Schmitz et al. 2001 (115), Trivedi et al. 2004 (116), Kooi et al. 2003 (117), Trivedi et al. 2004 (118), Trivedi et al. 2006 (119), Tang et al. 2007 (120), Tang et al. 2008 (121), Sadat et al. 2013 (122)</td>
</tr>
<tr>
<td>Rausch et al. 2001 (37) and 2002 (38), Kleinschnitz et al. 2003 (39), Schroeter et al. 2004 (40), Wiart et al. 2007 (41), Frechou et al. 2013 (42)</td>
<td>Abdominal aortic aneurysm</td>
<td>Richards et al. 2011 (125)</td>
</tr>
<tr>
<td>Yang et al. 2010 (44), Paulis et al. 2012 (91), Prötti et al. 2013 (43)</td>
<td>Diagnostic biomarkers</td>
<td>Cowles and Zhu 2012 (51), Ling et al. 2011 (52)</td>
</tr>
<tr>
<td>Cowles and Zhu 2012 (51), Ling et al. 2011 (52)</td>
<td>Acute coronary syndrome</td>
<td>Wilson et al. 2009 [PROTECT-TIMI 30 trial, (129)]</td>
</tr>
<tr>
<td>Lin et al. 2013 (48), Kim et al. 2013 (50)</td>
<td>Thrombosis</td>
<td></td>
</tr>
<tr>
<td>Treatment monitoring</td>
<td>Plaque stabilization</td>
<td>Tang et al. 2009 (130), Degnan et al. 2012 [ATHEROMA trial, (131)]</td>
</tr>
<tr>
<td>Marinescu et al. 2012 (53)</td>
<td>Ischemic stroke</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular therapy</td>
<td>Myocardial infarction</td>
<td>Chu-fan et al. 2011 (133)</td>
</tr>
<tr>
<td>Himes et al. 2004 (70), Sadek et al. 2008 (71), Kim et al. 2009 (72), Yao et al. 2011 (73), Kim et al. 2008 (74), Song et al. 2009 (75), Lee et al. 2009 (76), Guo et al. 2012 (77), Wang et al. 2011 (78), Zhang et al. 2013 (79), Riegler et al. 2013 (80)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myerson et al. 2011 (86), Palekar et al. 2013 (87), Ma et al. 2009 (88), Kawata et al. 2012 (89), Korin et al. 2012 (90)</td>
<td>Thrombolysis</td>
<td></td>
</tr>
<tr>
<td>Takamýa et al. 2011 (82) and 2012 (81), Yun et al. 2013 (83), Lu et al. 2014 (84)</td>
<td>Ischemic stroke</td>
<td></td>
</tr>
<tr>
<td>Chang et al. 2013 (93), Liu et al. 2013 (95), Zhang et al. 2012 (94), Binsalamah et al. 2011 (92)</td>
<td>Angina pectoris, myocardial infarction</td>
<td></td>
</tr>
<tr>
<td>McCarthy et al. 2012 (97), Winter et al. 2006 (98) and 2008 (134), Katsuki et al. 2013 (96)</td>
<td>Plaque stabilization</td>
<td>Margolis et al. 2007 [SNAPST-1 trial, (135)]</td>
</tr>
<tr>
<td>Joner et al. 2008 (106), Masuda et al. 2011 (108), Tsukie et al. 2012 (107), Polýak et al. 2008 (109)</td>
<td>In-stent restenosis</td>
<td></td>
</tr>
</tbody>
</table>
The feasibility of USPIO-enhanced MRI to detect inflammation following the ischaemic stroke was investigated by Saleh et al. (123). In this clinical phase II study, 10 consecutive patients received ferumoxtran (Sinerem/Combidex) infusion at the end of the first week after symptom onset. Two follow-up MRI scans were performed, at 24–36 h and 48–72 h after infusion. USPIO-induced signal alterations representing parenchymal enhancement were different from conventional gadolinium-enhanced MRI (Magnevist®, Schering), showed an increase over time, and corresponded to the distribution of macrophages. The authors concluded that increasing USPIO-enhancement on T1-weighted images indicates brain infiltration by USPIO-laden macrophages, and may provide an in vivo surrogate marker of cellular inflammation in stroke. More recently, the utility of USPIO-enhanced MRI for estimating macrophage infiltration into early ischemic stroke lesions was examined in another study from the same group (124). Patients with stroke received intravenous ferumoxtran followed by four subsequent MRI scans. In 3 of 9 analyzed patients, parenchymal USPIO enhancement was observed on T1-weighted spin-echo images. USPIO-dependent signal changes reflected the variable extent and distribution of macrophage infiltration in different lesion types, indicating that USPIO-enhanced MRI may help tailoring the anti-inflammatory therapy in patients with stroke.

As a further possible application, USPIO-enhanced MRI was tested for prediction of expansion and rupture of life-threatening aortic aneurysms (125). As their prognosis currently relies on the measurement of aneurysm diameter only, new techniques are urgently needed to assess the rate of AAA expansion. The study was carried out in 29 stable patients with asymptomatic AAA, who received MRI scans before and 24–36 h after administration of ferumoxtran. The study demonstrated that the patients with distinct mural uptake of USPIO had a 3-fold higher AAA growth rate than those with no or nonspecific USPIO uptake despite having similar aneurysm diameters. This indicated that the uptake of USPIO in AAA is capable of identifying cellular inflammation and can distinguish between slow and rapidly progressive aneurysm expansion, thus improving risk stratification in the patients.

Most recently, Yilmaz et al. (126, 127), tested the suitability of USPIO-based MRI contrast agents for characterization of myocardial infarct pathology as compared with conventional gadolinium-based imaging. The studies showed that the approved dose of ferucarbotran (Resovist®, NIMINI-1 trial) did not allow improved visualization of myocardial peri-infarct zone as compared to gadolinium-based contrast agent Magnevist® (126). In contrast, the administration of ferumoxytol (Rienso/Feraheme™, NIMINI-2 trial) in 14 patients with myocardial infarction allowed a better characterization of the injured myocardium and inflammatory macrophage accumulation, as well as the extent and composition of the peri-infarct zone, as compared with Magnevist® (127). Nearly in parallel, another clinical study utilizing ferumoxytol for USPIO-enhanced MRI to assess cellular myocardial inflammation following acute myocardial infarction was published (128). In line with the data of Yilmaz et al., this study showed a strong USPIO accumulation in the infarct tissue of patients with recent myocardial infarction, and a less pronounced uptake in the peri-infarct and remote myocardium. These findings indicate that a new generation of USPIO formulations with a favorable safety profile (138) allows non-invasive detection and characterization of the infarcted myocardium and rise hope for the rapid development of nanoparticulate and easily functionalized contrast agents with superior clinical and prognostic value.

Pilot studies – treatment monitoring and cardiovascular biomarkers

Apart from providing prognostic information and aiding disease diagnosis, nanoparticles can constitute a useful tool for monitoring the treatment efficacy and act as biomarkers for therapeutic interventions. Below, several clinical feasibility studies are described that highlight these important applications.

USPIO-enhanced MRI was first used to monitor the effects of aggressive vs. mild lipid-lowering therapy on macrophage burden in carotid plaques, in a randomized controlled study performed by the group of J.H. Gillard [ATHEROMA study, (130)]. Patients with moderate carotid stenosis, who demonstrated intraplaque accumulation of USPIO (ferumoxtran) on MRI at the baseline, received either 10 mg or 80 mg atorvastatin daily for 12 weeks. Twenty patients completed the treatment in each group. A significant reduction from baseline in USPIO-defined inflammation was observed in the 80-mg group at both 6 weeks and at 12 weeks. Moreover, aggressive lipid-lowering therapy for 12 weeks was associated with significant reduction in USPIO-defined inflammation as compared to the mild lipid-lowering treatment (130). This technique was thus suitable to assess therapeutic response in an interventional drug trial in humans, additionally facilitating enrollment of the specific patient cohort in the trial. The results of the long-term follow-up of the AHEROMA trial were published in 2012 (131), evaluating the ability of USPIO-enhanced MRI to predict subsequent cerebrovascular
and cardiovascular events. In those analyses, 62 patients initially screened for enrollment to Atheroma trial were examined for the occurrence of adverse cerebrovascular or cardiovascular events following the initial USPIO-imaging. Despite the small size of the study group and only 17 cardiovascular/cerebrovascular events reported in total, an association was observed (p=0.07) between the magnitude of maximal USPIO-induced signal intensity loss within carotid plaques and the risk of developing subsequent vascular events (131). As the study lacked adequate statistical power, future prospective studies with new generation of USPIO-based contrast agents are urgently needed. Such studies should incorporate long-term follow-up analyses in order to estimate the usefulness of USPIO-enhanced MRI for the assessment of future event risk in asymptomatic patients with carotid atherosclerosis.

Cell-based therapies are another attractive option for treatment of cardiovascular diseases. In this context, a safe and reliable method of tracking the cells in vivo to ensure the delivery of sufficient cell numbers to the diseased region is critical for the therapy development (69, 139). In their recent paper, Richards et al. (132) report the development of GMP-compliant method of labeling peripheral blood mononuclear cells (PBMCs) with SPION, and their successful tracking by MRI in humans. Labeling of the mononuclear cells with ferumoxides (Endorem/Feridex IV) did not affect their viability, migration or cytokine release in vitro, and allowed their MRI identification in vivo for at least 7 days. A phased-dosing study, demonstrated that systemic delivery of up to $10^{10}$ SPION-labeled cells in humans is safe and does not affect any hematological, biochemical, or coagulation variables. Therefore, 12 healthy volunteers received $10^6$–$10^8$ SPION-labeled cells approximately 27 h after a local cutaneous inflammation was induced in the thigh by intradermal injection of tuberculin. Intravenously delivered SPION-labeled cells were tracked to the inflamed skin at 24 and 48 h post-administration, as visualized by MRI and confirmed using Prussian blue staining of inflamed skin biopsies. The authors concluded that SPION-labeling is a safe and feasible technique that has a major potential for cardiovascular applications including monitoring of cell therapies and tracking inflammatory cells by MRI.

Myocardial injury estimated by cardiac troponin plasma or serum levels often goes unnoticed due to the low sensitivity of the current generation assays. In 2009, a pilot study was performed to evaluate the clinical value of a new ultra-sensitive nanoparticle assay for cardiac troponin I (nano-cTnI; detection limit 0.0002 μg/L) based on the sandwich antibody technique with chemical signal enhancement of gold nanoparticles to which the secondary antibody was bound [PROTECT-TIMI 30 trial, (129)]. In this study, blood samples from two cohorts were re-analysed: 50 patients with unstable angina and serial negative cTnI using current generation troponin assay, and 50 patients with definite myocardial infarction who had an initially negative current generation cTnI result, but results of sampling at 6–8 and 18–24 h revealed increase in cTnI. In the first cohort classified as UAP, 44%, 62%, and 82% of patients had an elevated nano-cTnI result measured at 0, 2, and 8 h with the nano-cTnI assay. In patients with definite myocardial injury but an initially negative cTnI, 72% and 98% had a positive nano-cTnI score (>0.003 μg/L) at 0 and 2 h. Thus, using a nanoparticle assay for cTnI, myocardial injury was detectable in a substantial proportion of patients previously classified as having unstable angina pectoris. The emergence of a new generation of troponin assays has the potential to improve the diagnosis of myocardial infarction based on an enhanced analytical performance at very low concentrations of troponin.

Pilot studies – disease treatment

In comparison to diagnostic applications, nanomedical approaches to treatment of cardiovascular disorders in humans remain limited. Two published pilot trials investigating the feasibility of nanoparticle-based drug delivery systems for treatment of angina pectoris and in-stent restenosis are briefly described below.

Angina pectoris resulting from myocardial ischemia affects about 50% of all patients with CAD. In a study by Chu-fan et al. (133), prostaglandin E1 (PGE1), an endogenous vasodilatory mediator effective in the treatment of critical limb ischemia, was tested in patients with angina pectoris undergoing a percutaneous coronary intervention (PCI). A randomized controlled trial utilizing PGE1 incorporated into lipid microspheres (lipo-PGE1) was conducted in 79 patients. Intravenous administration of lipo-PGE1 (20 μg/day for 5 days, starting at least 48 h before PCI) was well tolerated, with no serious adverse events or side-effects. With regard to the therapeutic effect, cardiac troponin T and creatine kinase myocardial isoenzyme concentrations were lower in the lipo-PGE1 group than in the control group at 6 h, 12 h and 24 h after PCI. The incidence of postprocedural myocardial injury was reduced in the lipo-PGE1 group by ca. 20% compared with the control group, indicating that lipo-PGE1 may improve patients’ outcomes following the elective PCI.

In-stent restenosis remains a significant limitation to the long-term patency of vascular stents. Drug-eluting stents inhibit restenosis but are associated with increased
risk of stent thrombosis (103). The only published safety and dose-finding human trial utilizing nanoparticle-based drug delivery system for in-stent restenosis (SNAPIST-I trial) utilized a novel 130-nm, albumin-bound particle form of paclitaxel (nab-paclitaxel) (135). Patients with angina received nab-paclitaxel at 10, 30, 70, or 100 mg/m² intravenously after bare metal stenting of de novo lesion in a single coronary artery. Data obtained for all 23 enrolled patients indicated that no significant adverse events were attributable to the nab-paclitaxel at 10 or 30 mg/m², although moderate neutropenia, sensory neuropathy and mild to moderate reversible alopecia occurred at higher doses. At 2 months post-procedure, no major adverse cardiac events were reported, whereas 4 target lesions required revascularization for restenoses at 6 months. The authors concluded that intravenous application of nab-paclitaxel was well tolerated at doses below 70 mg/m², suggesting that systemic nab-paclitaxel may be used with any available bare-metal stent and at potentially lower cost than DES (135). To date however, no evaluation is available as to the clinical efficacy of nab-paclitaxel for the suppression of coronary in stent restenosis.

Obstacles and considerations

**Imaging**

In spite of the promising results of the pilot studies in humans, the marketing and the clinical application of iron oxide-containing contrast agents are at the standstill. Although SPION and USPIO have been approved for clinical use in the past, currently they are scarcely available (see Table 2), with the exception of the oral iron oxide contrast agent, ferumoxsil (Lumirem/Gastromark), and ferumoxytol (Rienso/Feraheme), a novel intravenous agent approved for iron replacement therapy in chronic renal failure patients with iron-deficiency anemia.

The nephrotoxicity related to gadolinium-based contrast agents remains a concern. Because of the nanoparticle accumulation occurring typically in liver, spleen, kidneys and bladder, the retention of gadolinium can lead to a delayed serious adverse reaction known as nephrogenic systemic fibrosis in patients with impaired renal function (140). Although SPION/USPIO had been reported to have favorable safety profiles (141), the delayed toxicity effects due to an increased inflammation and oxidative stress cannot be excluded (142). New generation of iron oxide-based contrast agents with superior safety profile and targeting properties is thus needed for the future clinical imaging of atherosclerotic plaques, myocardial infarction, and ischemic stroke (138).

**Drug-delivery systems**

Nanoparticle-based drug delivery systems are an attractive platform to improve the efficacy and reduce the systemic toxicity of cardiovascular drugs. For the purpose of therapeutic applications, novel nanoparticle formulations, including drug-carrying liposomes, lipidots, and polycrylats are currently being developed. In order to deliver the therapeutic nanoparticles locally and to monitor the treatment efficacy, additional modifications are required, such as grafting of targeting-moiety and/or image contrast enhancement, leading to the development of complex multifunctional nanoparticles (Figure 2). However, manufacturing such intelligent, tissue- or cell-specific “theranostic” nanoparticles necessitates additional production

<table>
<thead>
<tr>
<th>Product</th>
<th>Trade name (EU)</th>
<th>Trade name (USA)</th>
<th>Availability</th>
<th>Marketed by (EU/USA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferumoxides</td>
<td>Endorem</td>
<td>Feridex IV</td>
<td>Discontinued in 2008</td>
<td>Guerbet/Berlex BayerHealthcare</td>
</tr>
<tr>
<td>Ferrixan (Ferucarbotran)</td>
<td>Resovist (Clavist)</td>
<td></td>
<td>Approved in EU 2001, production abandoned in 2009</td>
<td>Bayer Shering Pharma AG</td>
</tr>
<tr>
<td>Ferumoxtran-10</td>
<td>Sinerem</td>
<td>Combidx</td>
<td>Marketing authorization withdrawn in 2007</td>
<td>Guerbet/AMAG Pharma</td>
</tr>
<tr>
<td>Feruglose</td>
<td>Clariscan</td>
<td>NC100150, PEG-feron</td>
<td>Development discontinued due to safety concerns</td>
<td>GE Healthcare</td>
</tr>
<tr>
<td>Ferumoxil</td>
<td>Lumirem</td>
<td>Gastromark</td>
<td>FDA-approved 1996, available for sale</td>
<td>Guerbet/AMAG Pharma</td>
</tr>
<tr>
<td>Ferumoxytol</td>
<td>Rienso</td>
<td>Feraheme</td>
<td>FDA approved in 2009 for iron-replacement therapy; EU marketing authorization in 2012</td>
<td>Takeda/AMAG Pharma</td>
</tr>
</tbody>
</table>
steps and increases the costs of synthesis. Additionally, much more detailed characterization methods, as well as complex behavior in vivo must be considered, which increase the regulatory hurdles and hinder the clinical translation (143). Some of these considerations are discussed in detail below.

Nanoparticle characterization

Compared to the free drugs, nanosystems are extremely complex constructs and the lack of their comprehensive standardized characterization is a serious obstacle to overcome before they can obtain the approval for use in humans. Whereas high-sensitivity diagnostic nanosystems for ex vivo determination of the urine or serum biomarkers are likely to enter clinical practice in the near future, in vivo drug-delivery systems must be subject to a close toxicologic and pharmacologic scrutiny prior to the application in patients.

Nanoparticle chemical composition is often the most critical feature that affects their toxicity. For example, silver nanoparticles are reportedly more cytotoxic than gold nanoparticles (144, 145), but also dextran administration has been associated with some side effects, such as anaphylaxis, volume overload, pulmonary and cerebral oedema, or platelet dysfunction (146, 147). Acute renal failure is another rarely occurring but serious complication of dextran osmotic effect (148). Therefore, in patients with history of renal insufficiency, diabetes mellitus, or vascular disorders, large volumes of dextran-based drugs should be administered with particular caution.

Particle surface charge, indicated by zeta potential, has a strong influence on their stability in biologic fluids. Nanoparticles with a zeta potential above (±) 30 mV are usually stable in suspension, as the surface charge prevents their aggregation. Surface charge additionally influences the biologic effects: in vivo studies have shown that cationic liposomes can cause dose-dependent toxicity and pulmonary inflammation (149). Size is another of the critical factors that affect the behaviour of nanoparticles (150). An inherent difficulty related to its standardized characterization is that nanoparticle size can dramatically vary between different dispersion media, depending on their ionic strength and protein content. Generally, 10–100 nm particle size is considered optimal for drug delivery; the smaller size can cause undesirable effects such as passing through the blood-brain barrier, and the particles with diameter <5 nm are renally cleared which dramatically reduces their circulation time. In contrast, for delivery of drugs or imaging agents to atherosclerotic plaques, the nanoparticle diameter should not exceed 100 nm, as larger nanoparticles do not penetrate the vessel wall readily. Due to the small sizes of nanoparticles, their surface area is large. This provides various possibilities of surface modifications in order to stabilize and prevent aggregation of nanoparticles, and to allow conjugation of ligands or drugs. However, functionalization of the nanoparticles with ligands or antibodies can additionally contribute to their immunogenicity. Moreover, stability of surface coatings within biological environment and the possible side effects of degradation products must be considered. Nanoparticle agglomeration, which occurs due to their large surface area-to-volume ratio, is a factor that may affect their toxicity (151). Agglomeration is influenced by

Figure 2 Possible modifications of nanoparticles.
the particle composition, size and zeta potential, but also extrinsic factors, e.g., temperature, as well as pH, osmotic strength and the presence of serum in the dispersion media. For clinical applications, nanoparticle agglomeration may be a key factor limiting their use in patients, as it affects the physicochemical properties, bioavailability, and thus efficacy. As aggregated nanoparticles are no longer nano-sized, they undergo a rapid recognition by reticuloendothelial system (RES) and are cleared by the liver or spleen. Moreover, their presence in circulation may cause serious undesirable side-effects, such as clogging blood or lymphatic vessels (152). Prevention of agglomeration is therefore required for designing a stable, clinically safe nanosystem. In this respect, PEGylation of nanoparticles is considered a good solution to reduce their agglomeration and toxicity, and to increase their circulation time. By creating a hydrophilic layer around the nanoparticles, PEGylation provides a strong steric barrier to opsonin adsorption (153), therefore preventing nanoparticle recognition by the RES and increasing their circulation half-life.

The detailed and standardized characterization of the above-mentioned physico-chemical properties in physiologic fluids is the key issue to consider before any given nanosystem can enter the preclinical in vitro and in vivo testing. As different techniques for nanoparticle characterization are available (e.g., transmission electron microscopy, Fourier transform infrared spectroscopy, dynamic light scattering), each of them featuring its own advantages and limitations, optimally the characterization data obtained with several different measurement methods should be routinely compared to ensure reliable results. Detailed characterization can facilitate the prediction of nanoparticle effectiveness and toxicity in physiologic conditions and contribute to an improved design of stable, non-immunogenic constructs.

**Nanoparticle toxicity**

Characterization of the biological responses elicited by the nanosystems is critical for their future clinical applications. Although the concept of nanomedicine encompasses a localized delivery of nanosystems to target organs or tissues, their extended circulation time, as well as multiple degradation products, may result in cyto- and genotoxicity (154), as well as immunogenicity (155). Thus far, however, the basic cause-effect relationships are either not clearly demonstrated, or remain largely unexplored (156). Hence, detailed studies are urgently needed to identify various nanoparticle characteristics that can predict their toxicity. Due to this fact, nanotoxicology has emerged as an important area in the field of nanomedicine (152).

As stated above, physicochemical properties that may contribute to toxic effects of nanomaterials include chemical composition, charge, agglomeration state, particle size and surface properties (55). Among the currently investigated nanomaterials, the best safety profile i.e., the lowest toxicity was reported for PLGA, which thus has the best potential to be used in clinical applications. In the case of liposomes, the features that can predict their systemic toxicity are mainly related to their lipid composition and charge. Those characteristics should thus be considered when designing liposome-based drug-delivery systems in order to minimize the potential side effects (149, 157). Silica and titanium dioxide nanoparticles were reported to cross placenta barrier in mice and cause neurotoxicity in fetus, but these effects are abolished upon surface modification with carboxyl and amine groups (158). Among the metal oxide nanoparticles, iron oxide nanoparticles were reported to be non-cytotoxic for endothelial cells in vitro at concentrations below 0.1 mg/mL (159). Nonetheless, upon intravenous administration, their accumulation in liver and/or target tissue may potentially cause iron overload. Increased amounts of free iron can affect iron homeostasis and induce oxidative stress, leading to DNA damage and/or inflammation (142). However, the recent clinical study by Sadat et al. (122) provided evidence that USPIO nanoparticles are cleared out of the atherosclerotic plaques within 6 months post-application, and no adverse effects following multiple USPIO infusions were observed, confirming that these particles are clinically safe and well tolerated (138).

Other considerations related to nanosystem toxicity include their pyrogenicity and endotoxin contamination. Depending on the chemical/biological components and the production process, the final product may contain bacterial endotoxins (160), which can cause inflammatory response upon in vivo application, leading to the organ damage. The FDA-recommended high-sensitivity bacterial endotoxin test (limulus amoebocyte lysate assay) is commonly used in preclinical pharmaceutical development, but most nanoparticles interfere with the assay (160, 161). Alternate nanoparticle-compliant pyrogenicity tests are therefore urgently needed to assure the sterility of nanoparticles produced for clinical use (160).

In general, the toxicity of any nanosystem should first be evaluated in vitro on cultured cells, under conditions that resemble or mimic the physiological state in order to produce reliable data that predict in vivo responses (162). Following these extensive initial tests to assess the effect of nanoparticles on the components of blood, the first-contact cells (e.g., endothelial cells in the case of intravenous application) and the target cells, the regulatory toxicity studies in animals, usually rats and mice, should
be performed. Due to their size, nanoparticles typically remain in the circulation for considerable periods of time, and their in vivo behaviour and interactions with cellular and extracellular substrates may induce undesired effects, including hemolytic reactions, platelet and complement activation, reactive oxygen species production and genotoxicity. To assess acute single/repeated dose toxic effects and estimate maximum tolerated dose of nanoparticles in vivo, animals should be monitored over 14 days for body weight, organ weight indices, as well as behavioural, biochemical and histopathological changes. Longer time span is necessary to evaluate nanoparticle-mediated immunotoxicity and chronic toxicity. Moreover, the determination of pharmacokinetics, biodistribution, as well as the clearance rate and routes of degradation products must be performed (163), which is usually done by the detection of radiolabeled constituents in animal tissues harvested at different time points. In case of complex multi-component nanoparticles, the expense and the efforts required for these investigations are immense.

Characterization of nanoparticle-based agents in an animal system is an essential part of assessing both nanotoxicology and in vivo efficacy, and a vital requirement to fulfill before any nanosystem is approved for clinical use by the regulatory bodies. However, the number of difficulties associated with these safety assessment studies is enormous, as analyses of all individual constituents of a complex multicomponent nanoparticle are required. Nanotoxicologic characterization is thus an important area that must undergo both extensive development and prompt standardization to ensure nanosystems approval for use in humans (156, 163).

**Scale-up and GMP production**

Another major hurdle to overcome in the process of nanosystem approval for clinical use is the GMP-compliant production (164). Additionally, the research and development methods often involve a low volume production and, in case of some manufacturing technologies, scaling up the process may pose serious difficulties. Apart from this, the costs of synthesis must be considered, as well as the batch-to-batch reproducibility (163). The latter issue is a serious problem, and may lead to devastating clinical consequences as recently reported for ferumoxytol (Rienso), the whole batch of which had to be withdrawn from the Swiss market due to one case of death and several cases of drug-hypersensitivity. Therefore, the extensive batch characterization and safety assessments are required, as well as the chemical engineering and pharmaceutical efforts, to provide a platform for a large-scale production of high-quality therapeutic nanosystems.

**Administration route**

Lack of effective delivery methods constitutes one of the major obstacles hindering the development and clinical application of therapeutic nanosystems (165). In terms of patients’ acceptance, the best delivery route is usually represented by oral administration, however, few vasculo-protective nanoparticle formulations are thus far available in this form [e.g., PLGA-curcumin (166, 167), heparin-loaded nanoparticles (168, 169)]. Parenteral administration evades the problems related to gastrointestinal route, i.e., the poor absorption, gastrointestinal intolerance and/or non-compliance associated with oral preparations. However, parenteral administration of nanodrugs commonly tested in animal studies is suboptimal, as it necessitates a careful patient monitoring and can be expected to have a very low acceptance in patients. Joint efforts of bioengineers, toxicologists, clinicians and pharmacologists will be necessary to design and synthesize targeted drug-delivery systems which will combine an improved pharmacokinetics and biodistribution of the therapeutics with the patient-accepted formulation.

**Regulatory issues**

During the approval process of any novel drugs, the candidates are closely scrutinized with regard to their safety and efficacy in humans. Standard drugs are usually composed of a single active agent combined with inactive formulation aids. As the nanodrugs often represent multi-component formulations, new considerations arise concerning the regulated drug development and testing (143, 163). Thus far, due to the lack of clear guidelines and regulations applicable to nanomedicines, the responsible regulatory agencies examine each nanoparticle-based drug on a product-by-product basis. The in vivo behaviour of the multi-component nanoconstructs can, however, differ from the activities enticed by single-component system. Precise new guidelines for nanoparticle characterization are necessary, as well as uniform standardized methods for testing the toxicity and efficacy of nanosystems in preclinical animal models, in order to provide a transparent regulatory frame for the pharmaceutical industry.

Taken together, whereas the implementation of novel nanoparticle-based ex vivo diagnostic assays for cardiovascular biomarkers analysis can only be limited by the complexity of production or the high costs, much more
serious obstacles hinder the clinical application of nanoparticles for cardiovascular imaging or drug delivery (Figure 3). As shown by the promising results of the pilot clinical studies, imaging of atherosclerosis using USPIO-enhanced MRI harbours tremendous potential to monitor the disease progression and to influence prognosis, both in asymptomatic population, as well as in subjects at risk of future or recurrent cardiovascular events. Imaging nano-systems composed of e.g., approved nanoparticle-based contrast agents and a targeting moiety have a good chance to pass the in vivo efficacy and toxicity tests favourably and obtain the approval for clinical use. However, even then substantial clinical research will be necessary to verify the clinical utility and identify the category of patients in whom this type of evaluation will translate into the biggest clinical benefits. Although routine bedside application of nanoparticle-based cardiovascular drug-delivery systems still belongs to a distant future, interdisciplinary efforts and collaborative research programs move cardiovascular nanomedicine a step closer to reality.

From bench to bedside: conclusions

Despite multiple technical and regulatory constraints that currently hinder the widespread clinical application, the potential clinical impact of nanotechnology in terms of managing strategies to ultimately reduce the occurrence of cardiovascular events is enormous. The translation of basic research studies into the clinical trials represents one of the biggest challenges in this field. Apart from safety and efficacy issues, legal and financial aspects must be considered to ensure a rapid and secure implementation of the new techniques in clinical practice. Moreover, the acceptance of the industry is required in order to establish GMP-compliant production and marketing. Extensive efforts in the field of cardiovascular nanomedicine together with promising results of animal studies and early clinical trials rise hope that, before long, safe nanosystems integrating a theranostic component and a targeting moiety will be approved for the diagnosis and therapy of cardiovascular diseases. As the clinical experience remains limited, careful evaluation of nanosystems’ safety, as well as the validation of their diagnostic and prognostic value in clinical trials are urgently needed.

Acknowledgments: This work was supported by the EU project FP7-NMP-2012-LARGE-6-309820, the DFG grant CI162/2-1, and the Emerging Field Initiative of the University of Erlangen-Nuremberg project “TOP-Biomat”.

Received January 8, 2014; accepted March 5, 2014; previously published online April 9, 2014
References


Iwona Cicha studied Biology at the Jagiellonian University, Cracow, Poland. After obtaining her PhD in medical sciences at the Ehime Medical School, Ehime University, Japan, she moved to the University of Erlangen, Germany. She was a postdoctoral fellow in the Department of Nephrology in 2003, before joining the Department of Cardiology, where she obtained her habilitation in Experimental Medicine in 2012. She has an extensive research experience in the field of atherosclerosis, with focus on the role of inflammation and blood flow dynamics in plaque development and destabilization. Since July 2013, she has been leading the Cardiovascular Nanomedicine Unit at the Section of Experimental Oncology and Nanomedicine (SEON), University Hospital Erlangen, focusing on the projects involving the application of nanomedical strategies for the treatment of cardiovascular disease.

Christoph D. Garlichs, an experienced clinician specialized in interventional and experimental cardiology, studied Medicine and Philosophy in Berlin, Germany, and completed his doctoral thesis in 1996. He headed the Laboratories of Molecular Cardiovascular Research at the University of Dresden before becoming the Head of the Laboratory of Molecular Cardiology at the University of Erlangen-Nuremberg in 1998. He obtained his habilitation in Internal Medicine in 2002 and became Professor of Cardiology in 2008. Between 2007 and 2013 he was a Vice-Director in the Medical Clinic 2 (Cardiology, Angiology) of the University Hospital Erlangen. Since June 2013, he has been the head of the Internal Medicine Clinic at the DIAKO Hospital Flensburg, Germany, assuming clinical responsibility for cardiology, angiology, nephrology, and internal intensive care medicine.
Christoph Alexiou received his PhD in 1995 from the Medical School of the Technical University of Munich, Germany. After the internship in the Gastroenterology Department, he worked as physician and researcher at the Department of Otorhinolaryngology, Head and Neck Surgery of the Technical University and founded a research group focusing on local chemotherapy using magnetic nanoparticles (Magnetic Drug Targeting). In 2000, he received his degree as an ENT-Physician and in 2002 he moved to the ENT-Department in Erlangen, Germany, where he obtained his postdoctoral lecture qualification (Habilitation). He is an assistant medical director in the ENT-Clinic and leads the Section for Experimental Oncology and Nanomedicine (SEON). Since 2009, he holds the Else Kröner-Fresenius-Foundation-Professorship for Nanomedicine at the University Hospital Erlangen. His research focuses on Magnetic Drug Targeting and the application of magnetic nanoparticles into human trials. For his work, he received several national and international awards.